Preparing and presenting public or written testimony to legislative committees or regulatory boards is one way for our physicians and pharmacists to share their expertise in the delivery of community cancer care and protecting the patient-physician relationship. The US Oncology Network along with physicians and pharmacists within The Network have provided verbal and written testimony on important legislative and regulatory matters important to community cancer care across the US.
Federal Testimony
Barry Brooks, MD, with Texas Oncology, testifies before the Energy and Commerce Health Subcommittee Hearing on Keeping the Promise: Site of Service Medicare Payment Reforms.
May 21, 2014.
Debra Patt, MD, with Texas Oncology, testifies before the Energy and Commerce Health Subcommittee Hearing on The Obama Administration’s Medicare Drug Experiment: The Patient and Doctor Perspective.
May 17, 2016.
Debra Patt, MD, with Texas Oncology testifies before the Energy and Commerce Health Subcommittee Hearing on Opportunities to Improve the 340B Drug Pricing Program.
July 11, 2018.
State Testimony
Debra Patt, MD, with Texas Oncology, testifies before the Texas House Insurance Committee on How Prior Authorization Costs Patients Time & Money.
March 9, 2021. Scott Rushing, MD, with Compass Oncology, testifies before the Oregon Senate Committee on Finance and Revenue in support of legislation that would exempt receipts from the administration or dispensing of medication in a clinical setting other than a hospital, like Compass Oncology, from the corporate activity tax. February 8, 2023. Rupesh Parikh, MD, with Comprehensive Cancer Centers of Nevada, testifies before the Assembly Committee on Health and Human Services in support of policy that would require health benefit plans to provide coverage for biomarker testing. March 17, 2023. Kash Firozvi, MD, with Maryland Oncology Hematology, testifies before the Insurance and Pharmaceuticals Subcommittee on proposed anti-steering legislation.
March 8, 2023.
Randy Drosick, MD, with OHC Specialists in Cancer and Blood Disorders in Ohio, testifies before the Ohio House Insurance Committee in support for HB 451: Revising the Physician Administered Drug Law.
February 9, 2022. Diaa Osman, MD, with Texas Oncology, testifies before the Texas Senate Health and Human Services Committee on policy that would require health benefit plans to provide coverage for biomarker testing.
March 29, 2023.
Gury Doshi, MD, with Texas Oncology, testifies before the Texas House Insurance Committee on legislation that prohibits insurers and PBMs from requiring the patient receive their physician administered drugs via white-bagged. from a PBM/insurer owned or affiliated specialty pharmacy.
March 28, 2023.
Les Busby, MD, with Rocky Mountain Cancer Centers, testifies before the Colorado House Health & Insurance Committee on legislation that grants the commissioner of insurance the power to enforce prohibitions and requirements on Pharmacy Benefit Managers (PMBs) and the ability to impose penalties on PBMs that fail to comply with the law. March 14, 2023.
